HCPCS code J3110: Teriparatide injection billing guide

Key Takeaways

HCPCS code J3110 describes injection of teriparatide at 10 mcg per unit, used for Medicare and Medicaid billing of Forteo and Bonsity under the buy-and-bill model.

The standard daily dose of 20 mcg equals 2 units of J3110 per administration, so billing quantity must match administration records exactly.

Medicare Part B reimburses J3110 at ASP plus 6% for physician-administered injections; rates update quarterly and must be verified against current CMS ASP files.

Pabau’s claims management software supports HCPCS code entry, quantity validation, modifier prompts, and prior authorization tracking for injectable drug billing workflows.

HCPCS code J3110 is the Level II HCPCS code for injection of teriparatide, 10 mcg. It is assigned and maintained by the Centers for Medicare and Medicaid Services (CMS) as part of the J-code series, which covers drugs administered by injection. The code is active and billable for 2026.

Per the CMS HCPCS overview, Level II J-codes are used specifically for drugs, biologicals, and other supplies not covered by CPT. J3110 falls under this system because teriparatide is a physician-administered injectable, not a self-administered drug covered under Part D.

Teriparatide: Drug overview and clinical context

Teriparatide is a recombinant parathyroid hormone (PTH) analogue. Unlike bisphosphonates, which slow bone resorption, teriparatide actively stimulates osteoblast activity to increase bone formation. The FDA has approved it for treating osteoporosis in adults at high risk for fracture, including postmenopausal women, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis.

Two products use HCPCS code J3110. Forteo, manufactured by Eli Lilly, is the original brand. Bonsity is a biosimilar teriparatide (FDA-approved biosimilar designation; verify current approval status with the FDA). Both share the same J-code, so payers distinguish between them using the National Drug Code (NDC) on the claim, not the HCPCS code itself.

J3110 billing unit and dosing

Each unit of J3110 represents 10 mcg of teriparatide. The FDA-approved standard daily dose is 20 mcg, administered subcutaneously once daily. This means practices bill 2 units of J3110 per standard administration.

Billing quantity must match what was actually administered and documented in the patient record. Over-billing units relative to the administered dose is a common audit trigger for buy-and-bill injectable claims.

Medicare reimbursement and fee schedule for HCPCS code J3110

Medicare Part B reimburses HCPCS code J3110 under the buy-and-bill model at the Average Sales Price (ASP) plus 6%. This formula is standard for Part B physician-administered drugs, covering the practice’s acquisition cost plus a handling margin. ASP rates update quarterly; always verify the current rate against the CMS Physician Fee Schedule lookup before billing, as older figures will not reflect current payment amounts.

For practices tracking reimbursement trends, understanding revenue cycle management for injectable drugs helps frame why quarterly ASP updates matter for cash flow. A rate change mid-quarter can affect the profitability of the buy-and-bill model if the practice has pre-purchased inventory at the prior ASP.

Processing remittances efficiently is equally important. Electronic remittance advice from Medicare will reflect the J3110 payment at the applicable ASP rate for the date of service, not the billing date. Reconcile against the quarter in which the service was rendered.

Buy and bill process for teriparatide

The buy-and-bill model means the practice purchases teriparatide from a specialty pharmacy or distributor, stores it, administers it to the patient, and then bills J3110 to Medicare or the patient’s insurer. This differs from the pharmacy benefit (Medicare Part D), where the patient picks up the drug from a retail pharmacy and the practice has no acquisition cost.

Understanding the full medical billing workflow for buy-and-bill injectables helps prevent the most common errors: claim submission without proof of acquisition, billing for more units than purchased, or failing to document the administration site. Each of those gaps creates a recoverable overpayment risk.

1. Acquire the drug: Purchase teriparatide (Forteo or Bonsity) from a licensed specialty pharmacy or wholesaler. Retain the invoice and lot number for documentation.
2. Store correctly: Teriparatide requires refrigeration (2-8°C). Document the storage log to demonstrate integrity of the drug on the date of administration.
3. Administer and document: Inject subcutaneously per the prescribing information. Record the dose, units, site, lot number, and administering clinician in the patient chart.
4. Record wastage: If any drug from a single-use vial is discarded, document the amount for JW modifier reporting. Use JZ modifier if no drug was wasted.
5. Submit the claim: Bill J3110 with the correct unit count, applicable modifiers, NDC number, and paired ICD-10 diagnosis code. Include the administration code (96372) on the same claim.

Note: teriparatide is primarily administered in-office under physician supervision for Medicare Part B billing. If a patient self-administers at home, Part D typically covers the drug through the patient’s pharmacy benefit, and J3110 would not apply.

ICD-10 diagnosis codes for J3110 billing

Every J3110 claim requires a paired ICD-10-CM diagnosis code that establishes medical necessity. Teriparatide is indicated for osteoporosis with high fracture risk, so the relevant codes fall within the M80 and M81 series. Payers may deny claims where the diagnosis code does not justify teriparatide over first-line bisphosphonate therapy.

Select the most specific code available. For fracture claims, include the encounter qualifier (initial, subsequent, sequela). Code M81.0 is the most frequently paired diagnosis for teriparatide claims where treatment is initiated for high fracture risk without an acute fracture event.

Modifiers and place of service for J3110

Modifiers directly affect payment and audit risk for J3110 claims. Using the wrong modifier, or omitting a required one, is one of the fastest paths to denial or a post-payment audit. Submitting a clean claim submission for J3110 requires getting the modifier right before the claim leaves the practice.

CMS requires JW or JZ on all single-dose injectable claims for dates of service on or after January 1, 2023. Failing to include one of these modifiers will result in a claim edit. Document the vial size, amount administered, and any discarded drug amount in the patient record to support modifier selection. For related billing audit guidance, reviewing denial codes in medical billing helps identify which modifier errors most commonly trigger remittance denial reasons.

Place of service: J3110 billed from a physician office uses POS 11. Hospital outpatient settings use POS 22. The POS affects the Medicare payment rate, since the facility fee may be separate when billing in a hospital-based setting.

Prior authorization requirements for J3110

Traditional Medicare fee-for-service does not require prior authorization for J3110. However, Medicare Advantage plans and commercial payers almost universally require it for teriparatide, given its cost relative to first-line osteoporosis therapies. Criteria vary by plan year and payer, so treat these as illustrative, not universal.

• Confirmed osteoporosis diagnosis: DEXA scan T-score at or below -2.5, or documented history of fragility fracture
• Bisphosphonate treatment failure or intolerance: Most payers require documented failure of, or contraindication to, at least one bisphosphonate (alendronate, risedronate, or equivalent)
• High fracture risk documentation: FRAX score or clinical note establishing high absolute fracture risk
• Prescribing physician specialty: Some plans require the prescriber to be an endocrinologist, rheumatologist, or other specialist
• Duration limits: FDA labeling limits teriparatide use to a cumulative lifetime maximum of 2 years; payers will not authorize beyond this

Proactive insurance eligibility verification before the first teriparatide administration confirms whether prior authorization is required and what documentation the payer needs. Submitting J3110 without a required PA will result in denial, and appeals with retroactive authorization are not guaranteed. Building a denial management strategy specifically for high-cost injectable drugs reduces write-off risk when authorization gaps occur.

NDC numbers for teriparatide (Forteo and Bonsity)

CMS requires National Drug Code (NDC) reporting on all Part B drug claims, including J3110. The NDC identifies the specific product, manufacturer, and package size, allowing CMS to audit whether the billed HCPCS code matches the actual drug dispensed. Maintaining medical billing compliance for buy-and-bill injectables depends on accurate NDC reporting tied to each administration.

NDC numbers can change when manufacturers update packaging. Always source the NDC from the actual product invoice or current prescribing information rather than memorizing a number. Format the NDC on the claim in 11-digit format (5-4-2) with no dashes.

Related HCPCS codes and crosswalk

J3110 does not stand alone on most teriparatide claims. Administration codes and fallback codes appear alongside it depending on the billing scenario. Understanding the full code ecosystem reduces the risk of unbundling errors or missing a required companion code. For practices evaluating their full injectable drug billing workflows, a medical billing software comparison can clarify which platforms support HCPCS J-code entry with built-in crosswalk prompts.

Use the AAPC HCPCS code lookup or the PGM Billing HCPCS lookup tool to verify current code descriptions and status before each billing cycle.

How practice management software supports J3110 billing

Reference code sites tell you what J3110 means. They do not help you bill it correctly across a high volume of patients. The gap between knowing the code and submitting clean claims at scale is where practice management software earns its keep.

Pabau’s claims management software supports HCPCS J-code entry with quantity validation, so a coder entering 1 unit when the administered dose requires 2 units gets flagged before submission. The platform also supports superbill documentation with the full J3110 claim line: HCPCS code, units, modifier, NDC, and paired ICD-10 code in one workflow.

• HCPCS code entry with unit validation: Flags quantity mismatches between administered dose and billed units before claim submission
• Modifier prompts: Reminds billing staff to apply JW or JZ based on wastage documentation, reducing the most common J-code claim edits
• Prior authorization tracking: Links PA status to the claim, preventing J3110 submission without a required authorization on file
• NDC field enforcement: Requires NDC entry for Part B drug claims, ensuring CMS compliance at charge entry rather than post-denial
• HIPAA-compliant data handling: HIPAA-compliant billing software ensures patient and claim data is handled securely throughout the revenue cycle

The practical difference is catching J3110 billing errors at charge entry, not after a denial comes back from Medicare or a Medicare Advantage plan. Book a demo with Pabau to see how the claims workflow handles buy-and-bill injectable drugs in a practice setting.

Streamline your injectable drug billing

Pabau’s claims management tools support HCPCS J-code entry, quantity validation, modifier prompts, and prior authorization tracking. See how it handles buy-and-bill workflows in a live demo.

Book a demo

Conclusion

HCPCS code J3110 billing requires precise unit counting, accurate modifier selection (JW or JZ), NDC reporting, and prior authorization management that varies across payer types. Each of these variables is a potential denial point when handled manually or inconsistently.

Pabau’s claims management platform operationalizes the J3110 billing workflow, enforcing quantity validation, modifier prompts, and PA documentation at charge entry. To see how the system handles buy-and-bill injectables in practice, explore Pabau’s claims management features or speak with a specialist about your injectable drug billing setup.

Continue your research

Need guidance on the full medical billing lifecycle? What is medical billing covers the end-to-end billing workflow from charge capture through remittance reconciliation.

Dealing with repeated J-code claim denials? Denial management in healthcare outlines systematic strategies for reducing denial rates on high-cost injectable drug claims.

Want to understand how clearinghouses fit into HCPCS billing? Medical claims clearinghouse guide explains how claims are validated and routed before reaching Medicare and commercial payers.

Frequently Asked Questions